4 Result(s)
-
Article
Efgartigimod in the treatment of Guillain–Barré syndrome
Guillain–Barré Syndrome (GBS) is caused by immunoglobulin G (IgG) autoantibodies. Efgartigimod, a human IgG antibody Fc fragment that acts as a natural ligand for the FcRn, can increase IgG degradation, which ...
-
Article
Open AccessConstructing and Validating a Nomogram Model for Short-Term Prognosis of Patients with AChR-Ab+ GMG
This study aimed to establish and validate a nomogram prognostic model for predicting short-term efficacy of acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (GMG).
-
Article
Open AccessRelative frequencies and clinical features of Guillain-Barré Syndrome before and during the COVID-19 pandemic in North China
Most studies investigated the relationship between COVID-19 and Guillain-Barré syndrome (GBS) by comparing the incidence of GBS before and during the pandemic of COVID-19. However, the findings were inconsiste...
-
Article
Open AccessThe male-to-female ratio in late-onset multiple acyl-CoA dehydrogenase deficiency: a systematic review and meta-analysis
Late-onset multiple acyl-CoA dehydrogenase deficiency (MADD) is the most common lipid storage myopathy. There are sex differences in fat metabolism and it is not known whether late-onset MADD affects men and w...
